Hengrui Medicine (01276.HK) said at its 1H2026 results briefing it expects approvals for more than 40 pending marketing applications in 2027–28 across five therapeutic areas, highlighting potential blockbusters including SHR-A2009, a domestic first s

2026-09-10

Hengrui Medicine (01276.HK) said at its 1H2026 results briefing it expects approvals for more than 40 pending marketing applications in 2027–28 across five therapeutic areas, highlighting potential blockbusters including SHR-A2009, a domestic first single-target HER3 antibody-drug conjugate (ADC).

Other News
2026-09-10

Anthropic made the following predictions for several economic scenarios: In a moderate scenario, GDP in 2030 would be only 1.6% higher than the baseline without AI; in a significant scenario, it would be 8.3% higher, with knowledge worker wages essen

2026-09-10

Invesco Nasdaq Technology ETF said it will be suspended from market open on Sept. 11, 2026 and will resume trading at 10:30 on Sept. 11, 2026. Redemptions will be processed as usual during the suspension.